Course: Clinical Updates in Myelofibrosis: Improving Equitable Care of Patients in Rural and Underserved Communities
CME Credits: 0.50
Released: 2025-09-19
Myelofibrosis is a rare myeloproliferative neoplasm characterized by anemia, bone marrow fibrosis, splenomegaly, and leukemic progression. To expand treatment options, newer JAK inhibitors and other novel agents have been developed and evaluated in clinical trials. However, patients in rural and underserved communities often face barriers such as limited access to oncology specialists, long travel distances, and low clinical trial participation, making these advances less accessible. This on-demand CME/CE activity will review current guideline recommendations for diagnosis and risk stratification of myelofibrosis, highlight recent data on novel therapies, and outline best practices for treatment selection. Strategies for individualizing care and managing adverse effects, including anemia, will also be discussed. This enduring activity is a recorded session from Oncology Congress Spring 2025 that took place on June 14, 2025.
		  
			            Upon completion of this activity, participants should be better able to:          
View Full Course